Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.

Thompson, J A; Gold, P J; Markowitz, D R; Byrd, D R; Lindgren, C G; Fefer, A

Thompson, J A; Gold, P J; Markowitz, D R; Byrd, D R; Lindgren, C G; Fefer, A.

Affiliation

Thompson JA; University of Washington School of Medicine, Seattle, USA.

Cancer J Sci Am ; 3 Suppl 1: S29-34, 1997 Dec.

Article in En | MEDLINE | ID: mdl-9457390

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Immunotherapy; Interferon-alpha/administration & dosage; Interleukin-2/administration & dosage; Melanoma/therapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/economics; Carmustine/administration & dosage; Cisplatin/administration & dosage; Combined Modality Therapy; Dacarbazine/administration & dosage; Female; Humans; Immunotherapy/economics; Injections, Subcutaneous; Interferon alpha-2; L-Lactate Dehydrogenase/blood; Male; Melanoma/blood; Melanoma/mortality; Middle Aged; Prognosis; Recombinant Proteins/administration & dosage; Survival Rate; Tamoxifen/administration & dosage; Treatment Outcome

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Interleukin-2 / Interferon-alpha / Immunotherapy / Melanoma Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer J Sci Am Journal subject: NEOPLASIAS Year: 1997 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links